title: Clinical safety of tazarotene in the treatment of plaque psoriasis.
abstract: Oral retinoids are effective in the treatment of psoriasis, but their use is limited by concerns for teratogenic potential and systemic side effects. Tazarotene is a novel acetylenic retinoid undergoing clinical trials for the topical treatment of mild-to-moderate plaque psoriasis. The safety and tolerability of tazarotene 0.1% and 0.05% gels were examined in a series of preclinical and clinical trials. In preclinical studies topically applied tazarotene gel was nonmutagenic, noncarcinogenic, and nonteratogenic. Tazarotene gel was not sensitizing, phototoxic, or photosensitizing in a series of studies in human volunteers. Treatment-related systemic adverse effects were not observed in clinical trials involving approximately 2000 patients treated with tazarotene 0.1% or 0.05% gel for periods of up to 1 year. Adverse effects appear limited to manageable, mainly mild-to-moderate local skin irritation.
authors.affiliation: Department of Dermatology, University of Wales, College of Medicine, Cardiff.
authors.forename: R
authors.initials: R
authors.lastname: Marks
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D006801:Humans; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D011355:Prodrugs / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D012869:Skin Absorption / Q000187:drug effects
chemical_list: D003879:Dermatologic Agents; D009539:Nicotinic Acids; D011355:Prodrugs; D012176:Retinoids; C086827:tazarotene